Usually for a small cap or micro-cap stock to double, it is because of a buyout. A move today in Vermillion, Inc. (NASDAQ: VRML) has the shares up over 100% after the company reported that the American Medical Association (AMA) Current Procedural Terminology Panel voted to approve the company’s application for a Category 1 CPT code for its OVA1® test. The test is designed to help differentiate benign versus malignant ovarian masses.
Vermillion noted that there has been an unmet clinical need for this triage test. The company also noted that it will help streamline claims processing and accelerate further coverage and adoption by private payers. The AMA recently disclosed the new code on its website, which will become effective January 1, 2013.
What is amazing is that the gain of 114% to $2.85 is on 9 million shares. That is about 80-times normal trading volume. Yahoo! Finance also noted that the 52-week trading range is $0.97 to $7.60 and its market cap after this double-plus is still only almost $43 million.
We do not know if the company will use the opportunity to raise capital or not.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
